Soluble RAGE further stratifies risk of coronary artery and end-stage kidney disease in high-risk individuals with type 1 diabetes and treatment-resistant hypertension
Elevated sRAGE is associated with increased odds of TRH in individuals with type 1 diabetes. sRAGE further stratifies high risk of incident CAD and ESKD, even after accounting for clinical variables. Along with eGFR, sRAGE may help to identify individuals at the highest risk of adverse cardiovascular and kidney outcomes.
Authors
- Per‐Henrik Groop (ORCID: https://orcid.org/0000-0003-4055-6954)
- Markku Lehto (ORCID: https://orcid.org/0000-0001-8414-7285)
- Niina Sandholm (ORCID: https://orcid.org/0000-0003-4322-6942)
- Raija Lithovius (ORCID: https://orcid.org/0000-0001-7313-4710)
- Krishna Adeshara (ORCID: https://orcid.org/0000-0002-6960-5505)
- Stefan Mutter (ORCID: https://orcid.org/0000-0002-8293-6982)
- Valma Harjutsalo
Institutions
- University of Helsinki (FI)
- Baker Heart and Diabetes Institute (AU)
- Helsinki University Hospital (FI)
- Institute for Molecular Medicine Finland (FI)
- Folkhälsans Forskningscentrum (FI)
- Monash University (AU)
Publication Details
- Journal
- Cardiovascular Diabetology
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1186/s12933-025-03017-8
- Primary Topic
- Advanced Glycation End Products research
- Type
- article
- Field-Weighted Citation Impact
- 0.00